









市场行情
/
股票
/
nasdaq-abeo
/

Abeona Therapeutics Inc

ABEO

5.440USD

+0.330+6.46%

收盘 12/22, 16:00（美东）报价延迟15分钟

285.06M总市值

3.36市盈率 TTM



Abeona Therapeutics Inc

5.440

+0.330+6.46%

概览公司财务分析

概览

公司

财务

分析

关于 Abeona Therapeutics Inc 公司

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Abeona Therapeutics Inc简介



公司代码ABEO

公司名称Abeona Therapeutics Inc

上市日期Sep 19, 1980

CEOSeshadri (Vishwas)

员工数量136

证券类型Ordinary Share

年结日Sep 19

公司地址6555 Carnegie Ave, 4th Floor

城市CLEVELAND

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编44103

电话16468134701

网址https://abeonatherapeutics.com/

公司代码ABEO

上市日期Sep 19, 1980

CEOSeshadri (Vishwas)

Abeona Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Vishwas (Vish) Seshadri, Ph.D.

President, Chief Executive Officer, Director

1.19M

-0.02%

Mr. Michael Amoroso

Chairman of the Board

180.47K

Dr. Leila Alland, M.D.

Independent Director

154.37K

Mr. Donald A. Wuchterl

Independent Director

145.44K

-3.44%

Ms. Christine Berni Silverstein

Independent Director

120.48K

-9.80%

Mr. Mark J. Alvino

Independent Director

62.34K

-19.39%

Dr. Bernhardt G. Zeiher, M.D.

Independent Director

47.15K

Dr. Eric Crombez, M.D.

Independent Director

Mr. Joseph Vazzano, CPA

Chief Financial Officer

Ms. Faith L. Charles, J.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Vishwas (Vish) Seshadri, Ph.D.

President, Chief Executive Officer, Director

1.19M

-0.02%

Mr. Michael Amoroso

Chairman of the Board

180.47K

Dr. Leila Alland, M.D.

Independent Director

154.37K

Mr. Donald A. Wuchterl

Independent Director

145.44K

-3.44%

Ms. Christine Berni Silverstein

Independent Director

120.48K

-9.80%

Mr. Mark J. Alvino

Independent Director

62.34K

-19.39%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月4日周四

持股股东

股东类型

持股股东

占比

Nantahala Capital Management, LLC

8.42%

Adage Capital Management, L.P.

5.62%

BlackRock Institutional Trust Company, N.A.

5.26%

James Russell Revocable Trust

5.02%

Suvretta Capital Management, LLC

4.94%

其他

70.74%

持股股东

占比

Nantahala Capital Management, LLC

8.42%

Adage Capital Management, L.P.

5.62%

BlackRock Institutional Trust Company, N.A.

5.26%

James Russell Revocable Trust

5.02%

Suvretta Capital Management, LLC

4.94%

其他

70.74%

股东类型

持股股东

占比

Hedge Fund

29.19%

Investment Advisor

18.72%

Investment Advisor/Hedge Fund

9.68%

Individual Investor

5.33%

Corporation

5.02%

Research Firm

4.84%

Venture Capital

4.23%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

22.85%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

204

36.22M

79.02%

-9.77K

2025Q3

209

38.81M

82.28%

+643.18K

2025Q2

192

38.19M

68.92%

+5.47M

2025Q1

135

32.70M

74.05%

-3.55M

2024Q4

131

33.67M

75.84%

+1.89M

2024Q3

124

31.78M

82.54%

-3.17M

2024Q2

126

34.94M

52.06%

+14.17M

2024Q1

122

17.08M

56.78%

+1.44M

2023Q4

112

16.39M

53.86%

+3.77M

2023Q3

118

12.21M

54.85%

+1.48M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Nantahala Capital Management, LLC

4.56M

8.9%

+195.00K

+4.46%

Sep 30, 2025

Adage Capital Management, L.P.

3.07M

5.99%

+381.36K

+14.17%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.72M

5.3%

+2.24M

+475.57%

Jun 30, 2025

Suvretta Capital Management, LLC

2.68M

5.22%

-1.01M

-27.39%

Jun 30, 2025

The Vanguard Group, Inc.

2.51M

4.89%

+486.84K

+24.10%

Jun 30, 2025

Vivo Capital, LLC

1.84M

3.59%

Jun 30, 2025

Western Standard, LLC

2.09M

4.08%

-189.60K

-8.31%

Jun 30, 2025

Seshadri (Vishwas)

1.19M

2.32%

-44.27K

-3.59%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Propel Opportunities ETF

3.97%

iShares Micro-Cap ETF

0.04%

Proshares Ultra Russell 2000

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Russell 2000 Growth ETF

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 ETF

0.01%

Global X Russell 2000 ETF

0.01%

Vanguard US Momentum Factor ETF

iShares Core S&P Total U.S. Stock Market ETF

Simplify Propel Opportunities ETF

占比3.97%

iShares Micro-Cap ETF

占比0.04%

Proshares Ultra Russell 2000

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

iShares Russell 2000 Growth ETF

占比0.01%

ProShares UltraPro Russell2000

占比0.01%

iShares Russell 2000 ETF

占比0.01%

Global X Russell 2000 ETF

占比0.01%

Vanguard US Momentum Factor ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

公告日期

类型

比率

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

常见问题

Abeona Therapeutics Inc的前五大股东是谁？



Abeona Therapeutics Inc 的前五大股东如下：
Nantahala Capital Management, LLC持有股份：4.56M，占总股份比例：8.90%。
Adage Capital Management, L.P.持有股份：3.07M，占总股份比例：5.99%。
BlackRock Institutional Trust Company, N.A.持有股份：2.72M，占总股份比例：5.30%。
Suvretta Capital Management, LLC持有股份：2.68M，占总股份比例：5.22%。
The Vanguard Group, Inc.持有股份：2.51M，占总股份比例：4.89%。